Researchers from Emory University, the University of Wisconsin-Madison and UC-Berkeley have identified a significant opportunity for psilocybin-assisted therapy in the U.S. mental healthcare landscape. As U.S. News reported, if approved by the FDA, psilocybin could be used to treat depression, with an estimated 5.1 to 5.6 million Americans potentially benefiting from the therapy. Examining a group of patients undergoing treatment for depression, researchers determined that psilocybin could be a game-changing solution, particularly for individuals suffering from major depressive disorder (MDD) …